程红伟
厦门大学分子影像暨转化医学研究中心，澳门大学应用物理及材料工程研究院
通讯地址：厦门市翔安区翔安南路厦门大学分子影像中心
个人简介：
2014年获得淮阴师范学院生物工程工学学士学位，2017年获得厦门大学化学生物学理学硕士学位，2017-2018年于澳门大学攻读生物医药哲学博士学位，2023年获厦门大学生物化学与分子生物学专业理学博士学位，随后于澳门大学开展联合博士后研究。主要研究方向是以肝癌新颖分子靶标及其诊疗新策略为出发点，从事药物、基因递送研究。目前已发表论文五十余篇，其中以第一或通讯作者（含共同）在Adv. Mater., Sci. Bull., Adv. Healthc. Mater., J. Control. Release., Biomacromolecules等国际知名期刊上发表论文29篇，总影响因子超200，且有4篇文章入选ESI高被引论文；个人H因子为16，总引用超700次（谷歌学术）。受邀担任Acta. Biomater., Br. J. Pharmacol., J. Nanobiotechnol., Mater. Sci. Eng., C等三十余个SCI期刊审稿人。
教育及科研工作经历：
· 2023/07-至今 厦门大学、澳门大学联合博士后，合作导师：刘刚教授、曲松楠教授
· 2019/09-2023/06 厦门大学，分子影像暨转化医学研究中心，博士，导师：刘刚教授
· 2019/01-2019/08 厦门大学，分子影像暨转化医学研究中心，研究助理，导师：刘刚教授
· 2018/01-2019/01 澳门大学，中华医药研究院，生物医药，博士，导师：Richard D. Ye教授
· 2017/06-2018/12 厦门大学，药学院，研究助理，导师：吴云龙教授
· 2014/07-2017/06 厦门大学，药学院，化学生物学，硕士，导师：曾锦章教授、吴云龙教授
· 2010/09-2014/06 淮阴师范学院，生物工程，学士，导师：张瞳教授
研究兴趣：
主要研究方向是以肝癌新颖分子靶标及其诊疗新策略为出发点，从事药物、基因递送研究。近年来，专注SHIFT药物的基础及临床转化研究。
代表性论文：
(Citation >700, H-index =16, ESI highly cited paper: 4, #First author, *Corresponding author, Total IF >200)
1. Cheng H.#, Fan X.#, Ye E., Chen H., Yang J., Ke L., You M., Liu M., Zhang Y., Wu, Y.-L.*, Liu G.*, Loh, X. J.*, and Li, Z*. "Dual Tumor Microenvironment Remodeling by Glucose-contained Radical micelles for MRI Guided Photo-Immunotherapy". Advanced Materials, 2022, 34 (25): 2107674. (SCI impact factor: 32.086, JCR Q1, cited: 29)
2. Cheng, H.#, Wu, Z.#, Wu, C.#, Wang X., Liow, S, S., Wu, S., Li, Z., Wu, Y.-L*. "Overcoming STC2 mediated drug resistance through drug and gene codelivery by PHB-PDMAEMA cationic polyester in liver cancer cells". Materials Science and Engineering C-Materials for biological applications, 2018, 83: 210-217. (SCI impact factor: 8.457, JCR Q1, ESI high-cited paper, cited: 72)
3. Cheng, H.#, Fan, X.#, Wang, X., Wu, S., Li, Z., Loh, X. J., Wu, Y.-L*. "Hierarchically Self-Assembled Supramolecular Host-Guest Delivery System for Delivery of Chemotherapeutics to Drug Resistant Cancer Tumours". Biomacromolecules. 2018, 19(6): 1926-1938. (SCI impact factor: 6.978, JCR Q1, ESI high-cited paper, cited: 51).
4. Cheng, H.#, Fan, X.#, Wu, C., Wang, X., Wang, L.-J., Loh, X. J., Li, Z.*, Wu, Y.-L*. "Cyclodextrin-Based Star-Like Amphiphilic Cationic Polymer as a Potential Pharmaceutical Carrier in Macrophages". Macromolecular Rapid Communication, 2018, 40(5): e1800207. (SCI impact factor: 5.006, JCR Q1, cited: 29).
5. Cheng, H., Yang X., Liu G*. "Superstable homogeneous iodinated formulation technology: Revolutionizing transcatheter arterial chemoembolization". Science Bulletin, 2020, 65 (20):1685-1687. (SCI impact factor: 20.577, JCR Q1, cited: 16)
6. Liang X.#, Cheng H.#, Liu C., Liu G*. "Antigen self-presenting nanovaccine for cancer immunotherapy ". Science Bulletin, 2022, 67 (16): 1611-1613. (SCI impact factor: 20.577, JCR Q1, cited: 1)
7. Fan, X.#, Cheng, H.#, Wang, X., Ye, E., Loh, X. J., Wu, Y.-L.*, Li, Z*. "Thermo-responsive Supramolecular Chemotherapy by “V”-shape Armed β-Cyclodextrin Star Polymer to Overcome Drug Resistance". Advanced Healthcare Materials, 2018, 7(7): e1701143. (SCI impact factor: 11.092, JCR Q1, cited: 30).
8. Chen, H.#, Cheng, H.#, Dai, Q.#, Cheng Y.#, Zhang, Y., Li, D., Sun Y., Mao, J.*, Ren, K., Chu, C.*, Liu, G*. "A superstable homogeneous lipiodol-ICG formulation for locoregional hepatocellular carcinoma treatment". Journal of Controlled Release, 2020, 323: 635-643. (Co-first author, SCI impact factor: 11.467, JCR Q1, cited: 42)
9. Zhang Y.#, Cheng H.#, Chen H.#, Xu P.#, Ren E., Jiang Y., Li D., Gao X., Zheng Y., He P., Lin H., Chen B., Lin G., Chen A., Chu C.*, Mao J.*, Liu G.* "A pure nanoICG-based homogeneous lipiodol formulation: Toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization". European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49:2605–2617. (SCI impact factor: 10.057, JCR Q1, cited: 14)
10. Cheng, H., Tai. H. C*. "A nanovesicle platform to deliver neoantigens and immune checkpoint inhibitors: to ASPIRE for novel cancer vaccines". MedComm-Biomaterials and Applications, 2022, 1: e4. DOI: 10.1002/mba2.4.
11. Chen H.#, Teng M.#, Zhang H.#, Liang X., Cheng H.*, Liu G*. "Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma". Chinese Chemical Letters, 2022, 33: 3371-3383. (Co-corresponding author, SCI impact factor: 8.455, JCR Q1, cited: 3)
12. Chen, H.#, Cheng, H.#, Wu, W.#, Li, D., Mao, J.*, Chu, C.*, Liu, G*. "The Blooming Intersection of Transcatheter Hepatic Artery Chemoembolization and Nanomedicine". Chinese Chemical Letters, 2020, 31 (6): 1375-1381. (Co-first author, SCI impact factor: 8.455, JCR Q1, cited: 14)
13. Fan, X.#, Ke, L.#, Cheng, H.#, Chen, H., Li, Z-G., Ye, E., Loh, X. J., Wu, Y.-L.*, Liu, G.*, Li, Z*. "Enhanced drug retention by anthracene crosslinked nanocomposites for bimodal imaging-guided phototherapy". Nanoscale, 2021, 13, 14713-14722. (Co-first author, SCI impact factor: 8.307, JCR Q1, cited: 3).
14. Li Z.#, Cheng H.#, Mao J.*, Liu G*. "Conversion Therapy of Intermediate and Advanced Hepatocellular Carcinoma with Superstable Homogeneous Iodinated Formulation Technology". Science China-life science, 2022, 65, 2114-2117. (Co-first author, SCI impact factor: 10.420, JCR Q1, cited: 0)
15. Cao. L.#, Cheng. H.*, #, Jiang. Q., Li. H.*, Wu. Z*. "APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma". Aging-US, 2020, 12(5): 4573-4591. (Co-corresponding author, SCI impact factor: 5.955, JCR Q1, cited: 34)
16. Wu Z.#, Cheng H.#, Liu J.#, Zhang S., Zhang M., Liu F., Li Y., Huang Q., Jiang Y., Chen S., Lv L., Li D.*, Zeng JZ*. "The oncogenic and diagnostic potential of stanniocalcin 2 in hepatocellular carcinoma". Journal of Hepatocellular Carcinoma, 2022, 9:141-155. (Co-first author, SCI impact factor: 4.962, JCR Q2, cited: 1)
17. Fan, X.#, Cheng, H.#, Wu, Y., Loh, X. J., Wu, Y.-L.*, Li, Z*. "Incorporation of Polycaprolactone to Cyclodextrin-based Nanocarrier for Potent Gene Delivery". Macromolecular Materials and Engineering, 2018, 303: e1800255. (SCI impact factor: 4.402, JCR Q2, cited: 11)
18. Chan, B. Q. Y.#, Cheng, H.#, Liow, S, S., Dou, Q., Wu, Y.-L.*, Li, Z.*, Loh, X. J*. "Poly (carbonate urethane)-based thermogels with enhanced drug release efficacy for chemotherapeutic applications". Polymers, 2018, 10(1): 89. (SCI impact factor: 4.967, JCR Q1, cited: 27).
19. Ke, L.#, Li, Z-G.#, Fan, X., Loh, X.J., Cheng, H.*, Wu, Y-L.*, and Li, Z*. "Cyclodextrin-based hybrid polymeric complex to overcome dual drug resistance mechanisms for cancer therapy". Polymers, 2021, 13(8):1254. (Co-corresponding author, SCI impact factor: 4.967, JCR Q1, cited: 8).
20. Cao, L.#, Zhu, Y.#, Wu, Z., Wang, G., Cheng, H*. "Engineering nanotheranostic strategies for liver cancer". World Journal of Gastrointestinal Oncology, 2021, 13(10): 1213-1228. (Corresponding author, SCI impact factor: 3.404, JCR Q3, cited: 2).
21. Li, Z-G. #, Cheng, H. #, Ke, L-J., Liu, M., Wang, C., Loh, X. J., Wu. Y.-L.*, Li, Z.* "Recent Advances in New Copolymer Hydrogel-Formed Contact Lenses for Ophthalmic Drug Delivery". ChemNanoMat, 2021, 6(5): 564-579. (Co-first author, SCI impact factor: 3.820, JCR Q2, cited: 10)
22. Cao, L.#, Zhu, Y.#, Wang, W., Wang, G.*, Zhang, S.*, Cheng, H*. "Emerging Nano-based Strategies against Drug Resistance in Tumor Chemotherapy". Frontiers in Bioengineering and Biotechnology, 2021, 9: 798882. (Corresponding author, SCI impact factor: 6.064, JCR Q1, cited: 13).
23. Peng Y., He P., Gao X., Liu G*, Cheng H*. "A superstable homogeneous lipiodol-nanoformulation to overcome the dilemma of interventional embolization chemotherapy" Frontiers in Bioengineering and Biotechnology, 2022, 10:952194. (Corresponding author, SCI impact factor: 6.064, JCR Q1, cited: 0).
24. Zeng W.#, Zhang, C.#, Cheng, H.#, Wu, Y.-L., Liu, J., Chen, Z., Huang, J. G., Ericksen, R. E., Chen, L., Zhang, H., Wong, A. S., Zhang, X.-K., Han, W., Zeng, J.-Z*. "Targeting to the Non-genomic Activity of Retinoic Acid Receptor-Gamma by Acacetin in Hepatocellular Carcinoma". Scientific Reports, 2017, 7(1): 348. (SCI impact factor: 4.996, JCR Q1, cited: 19).
25. Huang, S.#, Cao, L.#, Cheng, H.*, Li, D., Li, Y, Wu, Z*. "The Blooming Intersection of Subfatin and Metabolic Syndrome". Reviews in Cardiovascular Medicine, 2021, 22(3): 799-805. (Co-corresponding author, SCI impact factor: 4.430, JCR Q2, cited: 2).
26. Xiong Y.#, He P.#, Zhang Y., Chen H., Peng Y., He P., Tian J., Cheng H.*, Liu G.*, Li J*. "Superstable homogeneous lipiodol-ICG formulation: Initial feasibility and first-in-human clinical application for ruptured hepatocellular carcinoma". Regenerative Biomaterials, 2023, 10, rbac106. (Co-corresponding author, SCI impact factor: 5.763, JCR Q1, cited: 0).
27. Cao L., Chen Y., Xu S.*, Cheng H*. "Is NAD(P)H quinone oxidoreductase 1 a tumor promoter or suppressor in gastric cancer?". Frontiers in Oncology, 2023, 13:1143108. (Corresponding author, SCI impact factor: 5.738, JCR Q2, cited: 0).
28. Cai J.#, Zhong M.#, Xu J., Cheng H.*, Xu S*. "Codelivery of Triptolide and IFN-γ to boost antitumor immunity for triple-negative breast cancer". International Immunopharmacology, 2023,120:110346. (SCI impact factor: 5.714, JCR Q1, cited: 0)
29. Peng Y.#, Cheng H.#, Liu H., Zhang Y., Liu G*. "Super-stable homogeneous embolic agents for transformation treatment of hepatocellular carcinoma". iRADIOLOGY, 2023. DOI: 10.1002/ird3.22.
30. Mao L., Ma P., Luo X., Cheng H., Wang Z.*, Ye E., Loh X., Wu, Y.-L.*, Li Z*. "Stimuli-Responsive Polymeric Nanovaccines Towards Next-Generation Immunotherapy". ACS Nano, 2023, 02273. (SCI impact factor: 18.027, JCR Q1, cited: 0)
31. Bai S., Lan Y., Fu S., Cheng H., Lu Z.*, Liu G*. "Connecting Calcium‑Based Nanomaterials and Cancer: From Diagnosis to Therapy". Nano-Micro Letters, 2022, 14:145. (SCI impact factor: 23.655, JCR Q1, cited: 5)
32. Chen H., Cheng H., Liang X., Cai S., Liu G*. "Immunosuppression reversal nanovaccines substituting dendritic cells for personalized cancer immunotherapy". Frontiers in Immunology, 2022, 13:934259. (SCI impact factor: 8.786, JCR Q1, cited: 0)
33. Chen H.#, Zhang P.#, Shi Y., Liu C., Zhou Q., Zeng Y., Cheng H., Dai Q., Gao X., Wang X.*, Liu G*. "Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy". Journal of Nanobiotechnology, 2022, 20(1):61. (SCI impact factor: 9.429, JCR Q1, cited: 3)
34. He P.#, Xiong Y.#, Ye J.#, Chen B., Cheng H., Liu H., Zheng Y., Chu C., Mao J., Chen A., Zhang Y.*, Li J.*, Tian J.*, Liu G*. "A clinical trial of super-stable homogeneous lipiodol-nanoICG formulation-guided precise fluorescent laparoscopic hepatocellular carcinoma resection". Journal of Nanobiotechnology, 2022, 20(1):250. (SCI impact factor: 9.429, JCR Q1, cited: 3)
35. He P.#, Ren E.#, Chen B.#, Chen H.#, Cheng H., Gao X., Liang X., Liu H., Li J., Li B., Chen A., Chu C., Chen X., Mao J.*, Zhang Y.*, Liu G*. "A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma". Theranostics, 2022; 12(4):1769-1782. (SCI impact factor: 11.600, JCR Q1, cited: 10)
36. Chu, C., Su, M., Zhu, J., Li, D., Cheng, H., Chen, X., Liu, G*. "Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment". Theranostics, 2019, 9(11):3134-3149. (SCI impact factor: 11.600, JCR Q1, cited: 60)
37. Wang, T., Qi, D., Yang, H., Liu, Z., Wang, M., Leow, W, Chen, G., Yu, J., He, K., Cheng, H., Wu, Y.-L., Zhang, H., Chen, X*. "Tactile chemomechanical transduction based on an elastic microstructured array to enhance the sensitivity of portable biosensors". Advanced Materials, 2019, 31(1): e1803883. (SCI impact factor: 32.086, JCR Q1, cited: 45)
38. Zhang, J., Zeng, Y., Su, M., Yu, M., Zhang, Y., Cheng, H., Zheng, H., Liu, J., Wang, X., Lei, Z., Chu, C., Liu, G*. "Multifunctional Ferritin Nanoparticles as Theranostics for Imaging-Guided Tumor Phototherapy". Journal of Biomedical Nanotechnology, 2019, 15(7): 1546-1555. (SCI impact factor: 3.641, JCR Q3, cited: 10)
39. Zheng, C., Gao, H., Yang, D.-P., Liu, M., Cheng, H., Wu, Y.-L.*, Loh, X. J*. "PCL-based Thermo-gelling Polymers for In Vivo Delivery of Chemotherapeutics to Tumors". Materials Science and Engineering C-Materials for biological applications, 2017, 74: 110-116. (SCI impact factor: 8.457, JCR Q1, ESI high-cited paper, cited: 51).
40. Dai Q.#, Wang L.#, Ren E., Chen H., Gao X., Cheng H., An Y., Chu C.*, Liu G*. "Ru-based Metal‐Organic Nanoradiosensitizers Enhance Radiotherapy by Combining ROS Generation and CO Gas Release". Angewandte Chemie International Edition, 2022. DOI: 10.1002/ange.202211674. (SCI impact factor: 16.823, JCR Q1, cited: 0).
41. Miao F., Lin H.*, Yao T., Zhang R., Sun X., Cheng H., Gu L., Xia X., Wu T., Li W.*, Liu G*. "A topical platelet-independent multilevel clotting initiator for intraoperative hemostasis". Chemical Engineering Journal, 2022. DOI: 10.1016/j.cej.2022.139925. (SCI impact factor: 16.744, JCR Q1, cited: 0).
42. Lv P.#, Chen H.#, Cheng H., Liu X., Liu C., Zeng Y., Jiang L., Wang X., Mao J.*, Liu G*. "A calcium alginate hydrogel microsphere-based transcatheter arterial viroembolization strategy for hepatocellular carcinoma". Advanced Therapeutics, 2022. DOI: 10.1002/adtp.202200174. (SCI impact factor: 5.0, JCR Q2, cited: 0).
43. Chen, H., Cheng, H., Ren, E., Mao, J., Liu, G*. "Water in milk exists, together achieving more: Harnessing superstable homogeneous iodinated formulation technology for clinical medicine". Chinese Science Bulletin, 2020, 65 (24): 2538-2540.
44. Shi, X.#, Xu, D.#, Cheng H., Chu, C.*, Liu, G*. "Recent Advances in Interventional Fluorescence Imaging: Toward the Precise Visualization of Transarterial Mini-Invasive Delivery Systems". Accounts of Materials Research, 2023, DOI: 10.1021/accountsmr.2c00195.
45. Xu, X.#, Chen, H.#, He, P.#, Zhao, Z., Gao, X., Liu, C., Cheng, H., Jiang, L., Wang, P., Zhang, Y., Wen, X., Li, Y., Huang, j., Xiong, Y., Mao, J., Ma, H.*, Liu, G*. "3D Hollow Porous Radio-Granular Hydrogels for SPECT Imaging-Guided Cancer Intravascular Brachytherapy". Advanced Functional Materials, 2023, e202215110.
46. 周俊强，梅子阳，罗潇潇，程红伟，毛景松，刘刚，赵扬*。 "肝动脉介入栓塞手术机器人设计及栓塞效果评价"。生命科学仪器，2021，1671-7929。
47. Lin G., Zhou J., Cheng H., Liu G*. "Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges". Small, 2023, e2207973.
48. Li D.#, Cai S.#, Wang P., Cheng H., Cheng B., Zhang Y.*, Liu G*."Innovative design strategies advance biomedical applications of phthalocyanines". Advanced Healthcare Materials, 2023, e202300263.
专利：
1. 刘刚，程红伟，高兴，楚成超，代奇轩。一种皮肤长效低毒驱虫软膏和超临界二氧化碳流体制备方法及其应用。专利号：ZL202110256222.X
2. 刘刚，陈虎，程红伟，张洪瑞，高兴。一种血管栓塞可注射明胶-碘油均相制剂的制备方法与应用。专利号：ZL202111279739.7
3. 刘刚，潘金韬，程红伟，高兴，楚成超。一种超稳定均相混合系统。专利号：ZL 2021 2 0225983.4
4. 刘刚，张阳，何攀，楚成超，程红伟，陈标奇。一种化疗药物纳米颗粒-碘油超稳定均相化栓塞剂的制备方法。专利号：ZL202111279694.3
5. 刘刚，楚成超，代奇轩，许大壮，程红伟。一种纳米药物-碘油均相制剂及其制备方法和应用。专利号：ZL202110256221.5
6. 刘刚，程红伟，陈虎，楚成超。一种药物掺杂的均相乙醇化学消融合剂的制备。公开号：CN113952476A
7. 刘刚，楚成超，张阳，程红伟， 陈爱政。一种纯药纳米颗粒制备装置及方法。公开号：CN110478246A
8. 楚成超，刘刚，李炜，吴益明，叶锦法，程红伟。一种胶原蛋白组装眼药、制备方法及应用。公开号：CN114831930A
获奖及荣誉：
1．中华医学会第二十六次全国放射学学术大会，口头报告，最佳论文奖，报告题目：Superstable Homogeneous System of Drug-Iodine Oil and Its Application in Transarterial Embolization and Fluorescence Surgery of Hepatocellular Carcinoma。
2．项目名称：“基于功能化影像探针的肿瘤诊疗新技术及应用”，厦门市科学技术进步奖二等奖，主要完成人。获奖人：刘刚、张献忠、楚成超、程红伟、王骁勇、尹震宇、李文岗、潘金韬。
3．项目名称：“肿瘤诊疗一体化分子影像探针设计、构建及临床应用研究”，福建省医学科技奖二等奖，主要完成人。获奖人：刘刚、张献忠、楚成超、程红伟、毛景松、王骁勇、尹震宇。
4．中国毒理学会2023纳米毒理学分会，口头报告，Nanoscale & Nanoscale Advances优秀论文奖。报告题目：可视化的TEMPO基聚合物在肝癌诊疗中的研究。
